sur AI/ML Innovations Inc. (isin : CA00143Y1034)
AIML Realigns Strategy with Exit from Tech2Heal
AI/ML Innovations Inc. (AIML) has officially exited its stake in Tech2Heal SAS, a digital health company based in France. The move comes after AIML reported an impairment loss in 2024 following an assessment of its investment in Tech2Heal. AIML had held an 11.11% equity stake in Tech2Heal.
The agreement, dated March 21, 2025, involves AIML giving up its equity position, board seat, and exclusive rights to Tech2Heal's products in North America. In exchange, Tech2Heal will return AIML's shares and its equity in AI RX Inc. Fabrice Pakin, Tech2Heal's CEO, also resigned from AIML's board.
Paul Duffy, AIML's CEO, emphasized the company's commitment to digital health innovations, highlighting a continued focus on its core portfolio. AIML looks forward to future collaborations despite this strategic exit.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de AI/ML Innovations Inc.